Evidence map›Paper›PMID 32393267›Full record

Observational studyBMC health services research2020

Impact of antimicrobial stewardship fee on prescribing for Japanese pediatric patients with upper respiratory infections.

Yuichi Muraki, Yoshiki Kusama, Masaki Tanabe, Kayoko Hayakawa, Yoshiaki Gu, Masahiro Ishikane, Daisuke Yamasaki, Tetsuya Yagi, Norio Ohmagari

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in BMC health services research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Prescribed daily-dose-based metrics of oral antibiotic use for hospitalized children in Japan.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Yuichi MurakiDepartment of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, 5, Misasagi-Nakauchi-cho, Yamashina-ku, Kyoto-shi, Kyoto, 607-8414, Japan. y-muraki@mb.kyoto-phu.ac.jp.ORCID http://orcid.org/0000-0001-6951-5676
Yoshiki KusamaAntimicrobial Resistance Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Masaki TanabeDepartment of Infection Control and Prevention, Mie University Hospital, Mie, Japan.
Kayoko HayakawaAntimicrobial Resistance Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Yoshiaki GuAntimicrobial Resistance Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Masahiro IshikaneAntimicrobial Resistance Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Daisuke YamasakiDepartment of Infection Control and Prevention, Mie University Hospital, Mie, Japan.
Tetsuya YagiDepartment of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Norio OhmagariAntimicrobial Resistance Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
National Center for Global Health and Medicine · JPMie University Hospital · JPKyoto Pharmaceutical University · JPNagoya University · JP

Funding

Ministry of Health, Labor and Welfare grant number H29-shinkougyousei-shitei-005Ministry of Health, Labor and Welfare grant number H30-shinkougyousei-shitei-005
6 · The paper itself

Abstract

backgroundIn 2018, the Japanese medical reimbursement system was revised to introduce a fee for the implementation of an antimicrobial stewardship (AS) fee for pediatric patients. The purpose of this study was to evaluate physicians' prescription behavior following this revision.

methodsWe conducted a retrospective observational study from January 1, 2017 to September 30, 2018 of pediatric (< 15 years) outpatients with upper respiratory tract infections (URIs). To assess the pattern of antibiotic prescription for the treatment of pediatric URIs before and after the introduction of the AS fee, we extracted data on pediatric URIs, diagnosed during the study period. Patients were divided based on whether medical facilities claimed AS fees. We defined antibiotic use as the number of antibiotics prescribed, and evaluated the proportion of each class to the total number of antibiotics prescribed. We also recorded the number of medical facilities that each patient visited during the study period.

resultsThe frequency of antibiotic prescription decreased after AS fee implementation, regardless of whether the facility claimed the AS fee, but tended to be lower in facilities that claimed the fee. Additionally, the frequency of antibiotic prescription decreased in all age groups. Despite the reduced frequency of antibiotic prescription, consultation behavior did not change.

conclusionsThe AS fee system, which compensates physicians for limiting antibiotic prescriptions, helped to reduce unnecessary antibiotic prescription and is thus a potentially effective measure against antimicrobial resistance.

Indexed as

Antimicrobial StewardshipPractice Patterns, Physicians'Anti-Bacterial AgentsChildDrug PrescriptionsFees and ChargesFemaleHumansJapanMaleOutpatientsRespiratory Tract InfectionsRetrospective StudiesAnti-Bacterial AgentsAntimicrobial resistanceAntimicrobial stewardshipFees and chargesPrescriptionsUpper respiratory tract infections

Identifiers

PMID32393267
PMCPMC7212615
OpenAlexW3028343894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.